Latest news with #Oppenheimer
Business Insider
2 hours ago
- Business
- Business Insider
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy' Stocks
After a rocky start to the spring, Wall Street came roaring back in May. President Trump's softened tariff stance reignited demand for risk assets, triggering the market's biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Confident Investing Starts Here: Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. 'The effects of the stock market rally from the lows seen on April 8 appear to us to augur positively for investors practicing diversification and patience notwithstanding near-term uncertainties… We remain overweight US equities and do not ascribe to the view that US exceptionalism is fading,' Stoltzfus noted. Against this backdrop, Oppenheimer analyst Jay Olson has picked out his winners for the months ahead, zeroing in on two stocks in particular – including one with the potential to jump ~550% by this time next year. We checked in with the TipRanks database to see how the rest of Wall Street views these names. The verdict? Both picks carry Strong Buy consensus ratings across the board, with substantial upside potential. Let's take a closer look at the details. Voyager Therapeutics (VYGR) One company Oppenheimer is especially bullish on is Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer's disease and Friedreich's ataxia – both of which have limited therapeutic options. Voyager's lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer's disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer's research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure. Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer's. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026. The promise of Voyager's TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich's ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones. Currently trading at $2.74 per share, VYGR may be flying under the radar – but Oppenheimer's Jay Olson sees it as a compelling entry point. 'We remain enthusiastic about VYGR's unique platform and optionality, and believe VYGR is well-positioned to pursue tau-targeting with different approaches. VYGR's strong balance sheet with a cash runway into mid-2027 should offer stability… Additionally, we are encouraged by the positive preclinical data, external validation of the platform technology through multiple collaborations with industry leaders, a strong management team, and our optimistic long-term view on the gene therapy and CNS therapeutic area,' Olson said. To this end, Olson rates VYGR an Outperform (i.e., Buy), and his $18 price target implies room for a stunning 556% upside potential in the next 12 months. (To watch Olson's track record, click here) Tvardi Therapeutics (TVRD) The second name catching Oppenheimer's attention is Tvardi Therapeutics, another biopharmaceutical firm – but a newcomer to the public markets. The TVRD ticker began trading on the NASDAQ on April 16 of this year, following the completion of a merger between Tvardi Therapeutics and Cara Therapeutics. Following its public debut, Tvardi is now focused on developing breakthrough therapies for fibrosis-driven diseases. Its approach centers on targeting STAT3 (signal transducer and activator of transcription 3), a key protein in the STAT family, known for its pivotal role in numerous cellular processes. At the center of Tvardi's clinical efforts is TTI-101, an oral small-molecule STAT3 inhibitor that selectively targets pY-STAT3 within the SH2 domain. Tvardi is advancing TTI-101 as a treatment for both hepatocellular carcinoma (HCC) and idiopathic pulmonary fibrosis (IPF), two diseases marked by high unmet need and limited effective therapies. Early clinical results have been encouraging. In a first-in-human Phase 1 trial involving patients with advanced solid tumors, including HCC, TTI-101 was well tolerated with no dose-limiting toxicities. Pharmacodynamic data confirmed target engagement, with biopsies showing reduced levels of activated STAT3. Tvardi expects topline data from its ongoing Phase 1b/2 REVERT Liver Cancer clinical trial in HCC to be available in the first half of 2026. Meanwhile, building on insights from the same trial, Tvardi is also advancing the REVERT IPF Phase 2 study – a randomized, double-blind, placebo-controlled trial evaluating TTI-101, both as a monotherapy and in combination with nintedanib, in patients diagnosed with IPF within the past seven years. On May 27, 2025, the company announced that enrollment was complete, with topline results expected in the fourth quarter of this year. The potential of TTI-101, based on its earlier clinical trial results and optimistic forecasts for the current trials, has not gone unnoticed by Oppenheimer's Olson. The analyst is encouraged by the possible long-term returns, assuming success in both the trial and regulatory process. 'We see an underappreciated opportunity for lead asset TTI-101 as we forecast ~$1.2B peak risk-adjusted sales in 2040. Blinded Ph2a interim data suggest that TTI-101 could reverse IPF progression, thus supporting favorable differentiation from key competitors, with detailed Ph2a results expected in 2H25 serving as a potential valuable inflection point. In HCC, we believe TTI-101 offers a novel, mechanistically distinct approach, with interim Ph1b/2 data suggesting synergy in combination with SoC ahead of topline results in 1H26. We leverage our expertise in IPF and HCC to inform our analysis, and view TVRD as well-capitalized through key catalysts… Based on our DCF valuation of TVRD, we believe that its shares remain underappreciated,' Olson stated. With that backdrop, Olson rates TVRD an Outperform (i.e., Buy), alongside a $65 price target, suggesting a potential upside of 129% from current levels. Overall, this new stock has picked up 4 analyst reviews since it went public, and all are positive – making the Strong Buy consensus rating unanimous. TVRD is currently trading for $28.34, and its $50.75 average price target suggests that the shares have a 79% upside lying in wait for the year ahead. (See TVRD stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Time of India
9 hours ago
- Entertainment
- Time of India
Karate Kid Legends box office collection day 1: Jackie Chan's film fails to beat Thunderbolts, earns Rs 1.75 crore
Karate Kid Legends box office collection day 1: Karate Kid Legends, which hit the screens on May 30, has opened to a decent response at the Indian box office. It, however, has received underwhelming reviews with critics panning the execution. Karate Kid Legends is a martial arts drama directed by Jonathan Entwistle. Karate Kid Legends takes a decent start in India Jackie Chan is in the spotlight because of the latest film Karate Kid Legends, which arrived in theatres yesterday. According to Sacnilk, a trade portal, it earned Rs 1.75 crore (nett) in India on the first day. The film benefited from the popularity of the Karate Kid franchise but the dull reviews worked against it. Karate Kid Legends has failed to beat the day 1 earnings of Thunderbolts. The Marvel film earned Rs 3.85 crore on the first day. This, however, is not too surprising as Marvel Cinematic Universe (MCU) titles enjoy a dedicated fan following in India. Moreover, Florence Pugh too is a known name in the market because of her work in Oppenheimer. Coming back to Karate Kid Legends, it is expected to witness growth today (May 31) as it is a weekend. However, the jump may not be as high as expected because of the average word-of-mouth. About Karate Kid Legends Karate Kid Legends is a martial arts drama written by Rob Lieber. The film centres on a Kung Fu prodigy who is forced to enhance his skills to succeed in a prestigious competition. It stars Jackie Chan, Ralph Macchio, and Ben Wang. The music is composed by Dominic Lewis.
Yahoo
16 hours ago
- Business
- Yahoo
Ulta's First-Quarter Beat Amid Tough Beauty Backdrop Prompts Price Target Boost at Oppenheimer
Ulta Beauty's (ULTA) strong quarterly results in a challenging environment prompted Oppenheimer to l Sign in to access your portfolio
Yahoo
17 hours ago
- Business
- Yahoo
Oppenheimer Raises ADI Price Target to $265 on Cyclical Recovery Hopes
Oppenheimer recently raised the price target on Analog Devices, Inc. (NASDAQ:ADI) to $265 from $225 and kept an Outperform rating on the shares ahead of quarterly results. ADI designs, manufactures, tests, and markets integrated circuits (ICs), software, and subsystems products. The advisory saw upside to Q2 results and Q3 outlook as an overdue cyclical recovery took root. Tariff noise was easing a bit but first half of the year pull-in activity likely muted second half seasonality, in Oppenheimer's view. The advisory viewed Analog Devices as a prime beneficiary of cyclical rebound in core auto/industrial. A technician working on power management in a semiconductor factory. In earnings for the first quarter, the company had reported earnings per share of $1.63, beating market estimates by $0.09. The revenue over the time was $2.42 billion, beating analyst expectations by $60 million. The shares are up over 27% in the past month following a US-China trade deal that has temporarily eased pressure on semis. While we acknowledge the potential of ADI, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADI and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 33 Most Important AI Companies You Should Pay Attention To and 30 Best AI Stocks to Buy According to Billionaires Disclosure: None.
CNBC
a day ago
- Automotive
- CNBC
Tesla's real value is their leadership in physical AI and autonomous vehicle, says Colin Rusch
Colin Rusch, Oppenheimer senior research analyst, joins 'Squawk Box' to discuss Tesla's recent stock move, Tesla's robotaxi and autonomous driving rollout, what's next for the company, and more.
